Skip to content
Evigrade
CriticalSelective mineralocorticoid receptor antagonist×Triazole derivatives, systemic antifungals

Updated · Methodology

Mechanism

CYP3A4 is the main enzyme that metabolises eplerenone (eplerenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and voriconazole is a strong inhibitor of this enzyme (voriconazole SmPC, European Medicines Agency, EMA). The pair has not been studied and the documents give no figures, but both voriconazole labels expect eplerenone levels to rise significantly (EMA; voriconazole prescribing information, US Food and Drug Administration, FDA). For comparison, ketoconazole, another strong CYP3A4 inhibitor, at 200 mg twice daily increased the eplerenone area under the concentration–time curve (AUC) by 441%, or 5.4-fold (AEMPS; eplerenone prescribing information, FDA). Eplerenone blocks mineralocorticoid receptors and can raise blood potassium, and the eplerenone SmPC names low blood pressure and hyperkalaemia as the most likely signs of overdose (AEMPS).

Symptoms

The main risks are hyperkalaemia and a fall in blood pressure. The eplerenone summary of product characteristics (SmPC) names them as the most likely signs of overdose and lists hyperkalaemia, dizziness, syncope, hypotension and orthostatic hypotension among adverse reactions (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hyperkalaemia is more likely in older people, in reduced kidney function and in diabetes (AEMPS). The US label adds proteinuria and concurrent use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, non-steroidal anti-inflammatory drugs and even moderate CYP3A inhibitors (eplerenone prescribing information, US Food and Drug Administration, FDA). The same label lists dizziness, diarrhoea, vomiting, a rapid or irregular heartbeat, leg swelling and difficulty breathing as warning signs (FDA).

Management

The combination is contraindicated. Both voriconazole labels name eplerenone among drugs that must not be combined with voriconazole. The metabolism of these drugs depends heavily on CYP3A4, and high levels are linked to serious or life-threatening reactions (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA; voriconazole prescribing information, US Food and Drug Administration, FDA). The eplerenone labels contraindicate eplerenone with strong CYP3A4 inhibitors (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; eplerenone prescribing information, FDA), and the voriconazole labels describe voriconazole as a strong inhibitor of this enzyme (EMA; FDA). In the US eplerenone label, this contraindication applies to all patients, not only to those treated for hypertension (FDA). In Spain, eplerenone is authorised only for heart failure (AEMPS). In people taking eplerenone, check serum potassium at the start of treatment and at every dose change (AEMPS). Check potassium and creatinine within 3–7 days of starting even a moderate CYP3A inhibitor (FDA). If serum potassium reaches 6.0 mmol/L or more, stop eplerenone, and restart at 25 mg every other day once potassium falls below 5.0 mmol/L (AEMPS). Treat hypotension with supportive care and hyperkalaemia with standard treatment. Haemodialysis does not remove eplerenone (AEMPS). The documents do not say how long to wait after stopping voriconazole before starting eplerenone. The voriconazole half-life depends on the dose, about 6 hours at 200 mg, and because of non-linear kinetics it does not predict elimination (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Eplerenone

Other interactions with Voriconazole